Krystal Biotech (KRYS) Competitors $147.49 -2.66 (-1.77%) Closing price 04:00 PM EasternExtended Trading$147.40 -0.09 (-0.06%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KRYS vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMCShould you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Krystal Biotech vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings. Do analysts prefer ITCI or KRYS? Intra-Cellular Therapies presently has a consensus target price of $109.70, indicating a potential downside of 16.81%. Krystal Biotech has a consensus target price of $213.75, indicating a potential upside of 44.93%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Krystal Biotech is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in ITCI or KRYS? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 13.7% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer ITCI or KRYS? In the previous week, Krystal Biotech had 30 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 31 mentions for Krystal Biotech and 1 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.29 beat Krystal Biotech's score of -0.06 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ITCI or KRYS? Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Which has preferable valuation and earnings, ITCI or KRYS? Krystal Biotech has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Krystal Biotech$290.52M14.67$89.16M$4.1635.45 Is ITCI or KRYS more profitable? Krystal Biotech has a net margin of 37.17% compared to Intra-Cellular Therapies' net margin of -14.07%. Krystal Biotech's return on equity of 14.64% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Krystal Biotech 37.17%14.64%13.28% SummaryKrystal Biotech beats Intra-Cellular Therapies on 12 of the 17 factors compared between the two stocks. Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRYS vs. The Competition Export to ExcelMetricKrystal BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.34B$2.96B$5.54B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio35.4519.7528.0119.82Price / Sales14.67303.17433.8198.96Price / Cash32.3842.5936.1658.27Price / Book4.487.678.125.65Net Income$89.16M-$55.28M$3.25B$257.91M7 Day Performance-0.46%2.50%0.97%2.09%1 Month Performance11.66%11.70%7.36%11.13%1 Year Performance-26.56%4.89%31.31%18.40% Krystal Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRYSKrystal Biotech4.5474 of 5 stars$147.49-1.8%$213.75+44.9%-27.6%$4.34B$290.52M35.45210Insider TradeAnalyst RevisionITCIIntra-Cellular Therapies0.9187 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9168 of 5 stars$20.52+1.1%$37.60+83.2%-18.0%$13.02B$3.12B11.662,682Analyst RevisionRDYDr. Reddy's Laboratories2.3577 of 5 stars$15.08flat$16.95+12.4%-6.6%$12.59B$325.54B22.8527,811News CoverageUpcoming EarningsMRNAModerna4.2835 of 5 stars$29.90-1.9%$46.61+55.9%-74.0%$11.79B$3.24B-3.425,800Trending NewsOptions VolumeAnalyst RevisionRGCRegencell Bioscience0.2214 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap UpHigh Trading VolumeVTRSViatris3.2683 of 5 stars$9.20-1.3%$10.40+13.0%-21.7%$10.94B$14.74B-2.9032,000Trending NewsQGENQIAGEN3.7474 of 5 stars$47.49-1.8%$49.40+4.0%+16.9%$10.75B$1.98B119.075,765Positive NewsASNDAscendis Pharma A/S3.6333 of 5 stars$175.98+1.0%$220.67+25.4%+27.9%$10.65B$393.54M-28.021,017Positive NewsBBIOBridgeBio Pharma4.6238 of 5 stars$43.50-1.1%$58.85+35.3%+67.0%$8.35B$221.90M-12.32400Analyst RevisionBPMCBlueprint Medicines1.0758 of 5 stars$128.40+0.0%$128.06-0.3%+13.2%$8.29B$508.82M-51.98640News CoveragePositive News Related Companies and Tools Related Companies ITCI Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives RGC Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives BBIO Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRYS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KRYS Stock Alerts